Novartis stock trades 0.19 percent above its Xetra close
Published on 10/11/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Novartis stock was EUR 128.21 in weekend trading on October 11, 2026.
- The price was 0.19 percent above the October 9 Xetra close of EUR 127.97.
- Novartis reported FDA approval for Rhapsido on October 7, 2026.
On October 11, 2026, Novartis stock was EUR 128.21 in weekend trading at Lang & Schwarz at 6:03 p.m. CEST, up 0.19 percent versus the EUR 127.97 close of the last Xetra trading day on October 9. Market context: Market report SMI.
The week in figures
The week ended at EUR 127.97 at Lang & Schwarz. The reported range was EUR 124.61 to EUR 128.88. The weekend price was EUR 0.24 above the October 9 close, equivalent to 0.19 percent.
The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.
Chronology of the week
On October 7, Novartis announced that the U.S. Food and Drug Administration had approved Rhapsido, or remibrutinib, as the first treatment for adults with symptomatic dermographism, according to the Novartis newsroom.
Dates of the coming week
The fetched Novartis release lists multiple-sclerosis presentations at MSToronto2026 on October 21 and October 23, including remibrutinib and Kesimpta data. The next Xetra session is scheduled for October 12.
Last Xetra trading day
The October 9 close at Lang & Schwarz was EUR 127.97. Xetra remains closed during weekend trading, while the Lang & Schwarz indication provides the current euro reference for investors in Germany.
